DOCSLIB.ORG

Downregulation of the Complement Cascade in Vitro, in Mice and in Patients with Cardiovascular Disease by the BET Protein Inhibitor Apabetalone (RVX-208)

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Downregulation of the Complement Cascade in Vitro, in Mice and in Patients with Cardiovascular Disease by the BET Protein Inhibitor Apabetalone (RVX-208) J. of Cardiovasc. Trans. Res. DOI 10.1007/s12265-017-9755-z ORIGINAL ARTICLE Downregulation of the Complement Cascade In Vitro, in Mice and in Patients with Cardiovascular Disease by the BET Protein Inhibitor Apabetalone (RVX-208) Sylwia Wasiak 1 & Dean Gilham1 & Laura M. Tsujikawa1 & Christopher Halliday1 & Cyrus Calosing1 & Ravi Jahagirdar1 & Jan Johansson2 & Michael Sweeney2 & Norman C. Wong1 & Ewelina Kulikowski1 Received: 21 December 2016 /Accepted: 17 May 2017 # The Author(s) 2017. This article is an open access publication Abstract Apabetalone (RVX-208) is an epigenetic regulator Abbreviations developed to treat cardiovascular disease (CVD) that targets APCS Amyloid P component serum BET proteins. Through transcriptional regulation RVX-208 BET Bromodomain and extraterminal modulates pathways that underlie CVD including reverse cho- BETi BET inhibitor lesterol transport, vascular inflammation, coagulation, and C4BP C4b-binding protein complement. Using transcriptomics and proteomics we show CAD Coronaryarterydisease that complement is one of the top pathways downregulated by CVD Cardiovascular disease RVX-208 in primary human hepatocytes (PHH) and in plasma CPN Carboxipeptidase N from CVD patients. RVX-208 reduces basal and cytokine- CRP C-reactive protein driven expression of complement factors in PHH and in chi- FB Factor B meric mice with humanized livers. Plasma proteomics of FD Factor D CVD patients shows that RVX-208 decreases complement HDL High-density lipoprotein proteins and regulators, including complement activators FH Factor H SAP and CRP. Circulating activated fragments C5a, C3b, FI Factor I and C5b-C6 are reduced by 51, 32, and 10%, respectively, IL-1 Interleukin-1 indicating decreased activity of complement in patients. As IL-6 Interleukin-6 complement components are linked to CVD and metabolic INFγ Interferon γ syndrome, including major acute cardiac events, modulating MACE Major adverse cardiac event their levels and activity by RVX-208 may alleviate risks asso- MASPs MBL-associated serine proteases ciated with these diseases. MBL Mannose-binding lectin PHH Primary human hepatocytes Keywords Epigenetics . Bromodomain . Bromodomain and PRRs Pattern recognition receptors extraterminal protein . Biomarker . Inflammation . TNFα Tumor necrosis factor α Complement cascade . Innate immunity . Cardiovascular disease; major acute cardiac event Associate Editor Emanuele Barbato oversaw the review of this article Introduction Electronic supplementary material The online version of this article The complement system is an essential component of the in- (doi:10.1007/s12265-017-9755-z) contains supplementary material, which is available to authorized users. nate immunity and a major trigger of host inflammatory re- sponses. As such, it helps immune cells fight infections and * Ewelina Kulikowski maintains homeostasis by eliminating pathogens, immune [email protected] complexes, debris, and apoptotic cells. The complement sys- tem is composed of more than 30 proteins, some of which are 1 Resverlogix Corp., Suite 300, 4820 Richard Road SW, secreted into the bloodstream by hepatocytes, while others are Calgary, AB T3E 6L1, Canada associated with plasma membrane of many cell types. Most of 2 Resverlogix Inc., San Francisco, CA, USA circulating complement proteins participate in activation of J. of Cardiovasc. Trans. Res. the complement cascade, serving as enzymes, enzyme cofac- component. Specifically, excessive complement expression tors, or precursors of biologically active fragments (reviewed and activity are implicated in several aspects of human in [1]; see Fig. 1c). cardiometabolic disease, including atherosclerosis, diabe- Depending on the context the complement system can be tes, metabolic syndrome, and acute coronary syndrome activated through three distinct pathways: classical, lectin, and (reviewedin[4]). alternative, each leading to a common terminal C5-driven path- Apabetalone (RVX-208) is an orally available small mole- way (reviewed in [1]; see Fig. 1c). The classical pathway is cule developed for the treatment of cardiovascular disease activated by C1q which recognizes antigen-antibody com- (CVD) that targets epigenetic regulators bromodomain and plexes, microbial and apoptotic cells, and soluble pattern rec- extraterminal (BET) proteins BRD2, BRD3, and BRD4 [5]. ognition receptors (PRRs) such as the C-reactive protein Mechanistically, RVX-208 precludes interactions of BET pro- (CRP). In association with C1s and C1r, C1q propagates sig- teins with acetylated lysines on histone tails that normally naling through C4 and C2, leading to C3 cleavage and activa- promote active transcription [5, 6]. This inhibition is mediated tion. The lectin pathway is activated by soluble PRR mannose- through binding of RVX-208 to bromodomains 1 and 2 of binding lectins (MBLs), ficolins, and collectins. Subsequently, BET proteins [5, 6]. Of note, RVX-208 binds preferentially activation of MBL-associated serine proteases (MASPs) leads to BD2, which differentiates it from pan-BET inhibitors that to cleavage and activation of C3. Lastly, the alternative path- target BD1 and BD2 with equal affinity [6]. RVX-208 is the way involves a spontaneous cleavage of C3 in conjunction with first BET inhibitor (BETi) to enter human clinical trials for factor B, factor D, and properdin, making C3 an integrator of treatment of chronic disease, and analysis of its in vivo activity all the signals that stimulate the complement cascade. Cleavage is ongoing [7–10]. A post hoc analysis of pooled data from of C3 generates the C3b fragment which in turn cleaves and phase IIb trials SUSTAIN and ASSURE showed that RVX- activates C5, the initiator of the terminal pathway. The cleavage 208 treatment moderately enhances the plasma lipid profile by fragment C5b associates with C6, C7, C8, and C9 to form C5b- increasing high-density lipoprotein cholesterol (HDLc) and 9 on the membrane of target cells, leading to cell perme- ApoA-I while substantially lowering the incidence of major abilization and lysis. Soluble C5b-containing end products of adverse cardiac events (MACE) in CVD patients [10]. These complement activation are eliminated by clusterin and data prompted an investigation of beneficial effects of RVX- vitronectin to avoid unwanted association with non-target 208 beyond the improvement of the lipid profile. Of note, membranes. Cleavage of C3 and C5 not only promotes cell BET inhibition by RVX-208 reduces atherosclerosis and ex- lysis but also contributes to inflammation and leukocyte recruit- pression of inflammatory markers in the ApoE mouse knock- ment through anaphylatoxic activity of the C3a and C5a frag- out model [11 , 12]. In cultured primary human hepatocytes ments. These are inactivated by carboxypeptidase N that RVX-208 modulates expression of genes and pathways that cleaves their C-terminal arginine residue to yield C3a-desArg underlie CVD, including reverse cholesterol transport, vascu- and C5a-desArg. There are multiple proteins which downreg- lar inflammation, coagulation, and complement [10]. Here, ulate complement activity, including regulators of the classical using transcriptomics, real-time PCR, ELISA assays, and pro- and lectin pathways C1 inhibitor and C4b-binding protein, and teomics, we demonstrate that the complement cascade is regulators of the alternative pathway Factor H and Factor I. broadly and coordinately downregulated by RVX-208 in pri- Extensive cross talk between the coagulation and complement mary human hepatocytes (PHH), in mice and in CVD patients. pathways also leads to activation of C3 and C5 via extrinsic Our studies clearly indicate that RVX-208 impacts comple- proteases of the coagulation system (reviewed in [2]). ment protein abundance and activation in vivo, and suggest Specifically, thrombin and activated coagulation factors IXa, that complement repression by RVX-208 may contribute to Xa, XIa, and plasmin can directly cleave C3 and C5 to generate the decreased CVD risk and lower incidence of MACE ob- pro-inflammatory C3a and C5a. Factor XIIa has also been served in RVX-208 clinical trials. demonstrated to initiate classical pathway activation via cleav- age of C1r. Conversely, activated complement fragments C3a, C5a, and C5b-C9 are known to enhance platelet activation and Methods aggregation and promote thrombin generation on the platelet surface and fibrin formation, suggesting that complement acti- Tissue Culture vation may contribute to thrombus formation [3]. Complement expression and activity are tightly regulated Cryopreserved primary human hepatocytes (CellzDirect/Life to avoid immune dysregulation and host tissue damage. Both Technologies) were plated and then overlaid with Matrigel™ inefficient activation and overstimulation of complement can as recommended by the supplier. Cells were treated with com- be detrimental for the host, and is associated with increased pounds dissolved in DMSO (0.1% final concentration) and/or susceptibility to infectious diseases and non-infectious disor- cytokines for the indicated time in media recommended by the ders with an autoimmune and chronic inflammatory supplier supplemented with 10% fetal bovine serum (v/v). J. of Cardiovasc. Trans. Res. ac Complement RVX-208 JQ1 System Rank p-value Rank p-value PHH Donor 1 1/628 4.5E-7 8/628 2.4E-5 PHH Donor 2 22/628 2.0E-4 38/628 2.3E-3 b PHH Donor 1 PHH Donor 2 Gene Gene Name Symbol RVX-208 JQ1 RVX-208 JQ1 mannose-binding lecn (protein C) 2, soluble MBL2 0.09 0.07 0.25 0.25 complement component 9 C9 0.11
Load more

Recommended publications
  • Application Note
    APPLICATION NOTE Quantification of functional C5a using iLite® C5a Assay Ready Cells For research and professional use only. Not for use in diagnostic procedures. This application note contains a suggested protocol and performance data. Each individual laboratory must set up their own method and perform relevant validations. Background Complement component 5a (C5a) is a 74 amino acid small protein fragment of complement protein 5 (C5). C5 is cleaved to C5a and C5b by C5 convertase enzymes as a result of complement activation. Factors of the coagulation and fibrinolytic pathway are also able to cleave C5 to C5a. (1) C5a is a highly potent anaphylatoxin and chemoattracting peptide, with the ability to increase blood vessel permeability, stimulate cytokine release from myeloid cells, and expression of adhesion molecules on endothelial cells. (2) Main pro-inflammatory effector functions are induced by C5a binding to a seven-transmembrane G- protein-coupled receptor, C5aR1 (CD88). Rapidly after cleavage of C5 into C5a and C5b, C5a is metabolized by carboxypeptidases which removes the C-terminal arginine and forms C5a-desArg, a less potent ligand of C5aR1. C5a can also bind to a second receptor, C5aR2 (C5L2 or GPR77), however the biological effects associated with C5a binding C5aR2 are less well understood, both anti- inflammatory and pro-inflammatory effects have been described in literature. The C5a receptors are expressed in a wide range of cells and tissues, and the effect of C5a activation is dependent on the location of the C5a receptors. (3, 4) While the complement system is an important part of the innate immune defense against pathogens, research has shown that excessive complement activation including C5a-C5aR interaction plays a central role in several autoimmune and neurodegenerative disorders as well as in acute and chronic inflammatory conditions.
    [Show full text]
  • Impact of Liver-Derived Complement Component C5 on Atherosclerosis in Apoe-Deficient Mice
    Impact of Liver-derived Complement Component C5 on Atherosclerosis in ApoE-deficient Mice Zhe Ma München 2019 Aus dem Institut für Prophylaxe und Epidemiologie der Kreislaufkrankheiten Kliniker Ludwig-Maximilians-Universität München Direktor: Univ.-Prof. Dr. med. Christian Weber Impact of Liver-derived Complement Component C5 on Atherosclerosis in ApoE-deficient Mice Dissertation zum Erwerb des Doktorgrades der Naturwissenschaften an der Medizinischen Fakultät der Ludwig-Maximilians-Universität zu München vorgelegt von Zhe Ma aus Henan, China 2019 Mit Genehmigung der Medizinischen Fakultät der Universität München Betreuerin: Univ.-Prof. Dr. rer. nat. Sabine Steffens Zweitgutachter: PD Dr. rer. nat. Andreas Herbst Dekan: Prof. Dr. med. dent. Reinhard Hickel Tag der mündlichen Prüfung: 23. 07. 2020 Dean’s Office Faculty of Medicine Affidavit Ma, Zhe Surname, first name Hermann-Lingg Str. 18 Street 80336, Munich Zip code, town Germany Country I hereby declare, that the submitted thesis entitled Impact of Liver-derived Complement Component C5 on Atherosclerosis in ApoE-deficient Mice is my own work. I have only used the sources indicated and have not made unauthorised use of services of a third party. Where the work of others has been quoted or reproduced, the source is always given. I further declare that the submitted thesis or parts thereof have not been presented as part of an examination degree to any other university. Munich, 07 04 2020 Zhe Ma Place, date Signature doctoral candidate Affidavit September 2018 Impact of Liver-derived
    [Show full text]
  • Supplementary Table S4. FGA Co-Expressed Gene List in LUAD
    Supplementary Table S4. FGA co-expressed gene list in LUAD tumors Symbol R Locus Description FGG 0.919 4q28 fibrinogen gamma chain FGL1 0.635 8p22 fibrinogen-like 1 SLC7A2 0.536 8p22 solute carrier family 7 (cationic amino acid transporter, y+ system), member 2 DUSP4 0.521 8p12-p11 dual specificity phosphatase 4 HAL 0.51 12q22-q24.1histidine ammonia-lyase PDE4D 0.499 5q12 phosphodiesterase 4D, cAMP-specific FURIN 0.497 15q26.1 furin (paired basic amino acid cleaving enzyme) CPS1 0.49 2q35 carbamoyl-phosphate synthase 1, mitochondrial TESC 0.478 12q24.22 tescalcin INHA 0.465 2q35 inhibin, alpha S100P 0.461 4p16 S100 calcium binding protein P VPS37A 0.447 8p22 vacuolar protein sorting 37 homolog A (S. cerevisiae) SLC16A14 0.447 2q36.3 solute carrier family 16, member 14 PPARGC1A 0.443 4p15.1 peroxisome proliferator-activated receptor gamma, coactivator 1 alpha SIK1 0.435 21q22.3 salt-inducible kinase 1 IRS2 0.434 13q34 insulin receptor substrate 2 RND1 0.433 12q12 Rho family GTPase 1 HGD 0.433 3q13.33 homogentisate 1,2-dioxygenase PTP4A1 0.432 6q12 protein tyrosine phosphatase type IVA, member 1 C8orf4 0.428 8p11.2 chromosome 8 open reading frame 4 DDC 0.427 7p12.2 dopa decarboxylase (aromatic L-amino acid decarboxylase) TACC2 0.427 10q26 transforming, acidic coiled-coil containing protein 2 MUC13 0.422 3q21.2 mucin 13, cell surface associated C5 0.412 9q33-q34 complement component 5 NR4A2 0.412 2q22-q23 nuclear receptor subfamily 4, group A, member 2 EYS 0.411 6q12 eyes shut homolog (Drosophila) GPX2 0.406 14q24.1 glutathione peroxidase
    [Show full text]
  • Specifications of the NGS Panel Complement and Hemostasis Mediated Diseases| Page 1
    Specifications of the NGS panel Complement and hemostasis mediated diseases| page 1 Targeted sequencing with the Ion Torrent System is able to identify single nucleotide variants, small insertions and small deletions. Variants in repeat sequences, large homopolymers and large insertions/deletions are not or difficult to identify. The Sanquin NGS Panel complement/hemostasis (test code X001 to X006) includes 44 genes and regions of interest. Using this panel, the exones and intron/exon borders of the relevant genes are sequenced. For most proteins, functional/expression level testing is available (see request form no 10: immunodiagnostics and no 4: coagulation). Table 1: Genes covered by the complement/hemostasis targeted NGS panel. Encoded protein Context Gene Chr Chr. Positie OMIM alpha 2-antiplasmin Hemostasis/trombosis gene SERPINF2 17 17p13 613168 Factor IX Hemostasis/trombosis gene F9 X Xq27.1-27.2 300746 Factor V Hemostasis/trombosis gene F5 1 1q23 612309 Factor VII Hemostasis/trombosis gene F7 13 13q34 613878 Factor VIII Hemostasis/trombosis gene F8 X Xq28 300841 Factor XI Hemostasis/trombosis gene F11 4 4q35 264900 Tissue factor Hemostasis/trombosis gene F3 1 1p22-21 134390 Von Willebrand factor Hemostasis/trombosis gene VWF 12 12p13.3 613160 Factor XIIIa Hemostasis/trombosis gene F13A1 6 6p25.3-24.3 134570 Factor XIIIb Hemostasis/trombosis gene F13B 1 1q31-32.1 134580 gamma-glutamyl carboxylase Hemostasis/trombosis gene GGCX 2 2p12 137167 a Disintergrin and metalloproteinase wih thrombospondin repeats Hemostasis/trombosis gene
    [Show full text]
  • ESID Registry – Working Definitions for Clinical Diagnosis of PID
    ESID Registry – Working Definitions for Clinical Diagnosis of PID These criteria are only for patients with no genetic diagnosis*. *Exceptions: Atypical SCID, DiGeorge syndrome – a known genetic defect and confirmation of criteria is mandatory. Available entries (Please click on an entry to see the criteria.) Page Acquired angioedema .................................................................................................................................................................. 4 Agammaglobulinemia .................................................................................................................................................................. 4 Asplenia syndrome (Ivemark syndrome) ................................................................................................................................... 4 Ataxia telangiectasia (ATM) ......................................................................................................................................................... 4 Atypical Severe Combined Immunodeficiency (Atypical SCID) ............................................................................................... 5 Autoimmune lymphoproliferative syndrome (ALPS) ................................................................................................................ 5 APECED / APS1 with CMC - Autoimmune polyendocrinopathy candidiasis ectodermal dystrophy (APECED) .................. 5 Barth syndrome ...........................................................................................................................................................................
    [Show full text]
  • Comprehensive Genetic Analysis of Complement and Coagulation Genes in Atypical Hemolytic Uremic Syndrome
    BASIC RESEARCH www.jasn.org Comprehensive Genetic Analysis of Complement and Coagulation Genes in Atypical Hemolytic Uremic Syndrome † † † ‡ † Fengxiao Bu,* Tara Maga,* Nicole C. Meyer, Kai Wang, Christie P. Thomas, § † † Carla M. Nester, § and Richard J. H. Smith* § *Interdisciplinary PhD Program in Genetics, †Molecular Otolaryngology and Renal Research Laboratories, ‡Department of Biostatistics, College of Public Health, and §Rare Renal Disease Clinic, Departments of Pediatrics and Internal Medicine, Carver College of Medicine, University of Iowa, Iowa City, Iowa ABSTRACT Atypical hemolytic uremic syndrome (aHUS) is a thrombotic microangiopathy caused by uncontrolled activation of the alternative pathway of complement at the cell surface level that leads to microangiopathic hemolytic anemia, thrombocytopenia, and acute kidney failure. In approximately one half of affected patients, pathogenic loss-of-function variants in regulators of complement or gain-of-function variants in effectors of complement are identified, clearly implicating complement in aHUS. However, there are strong lines of evidence supporting the presence of additional genetic contributions to this disease. To identify novel aHUS-associated genes, we completed a comprehensive screen of the complement and coagulation pathways in 36 patients with sporadic aHUS using targeted genomic enrichment and mas- sively parallel sequencing. After variant calling, quality control, and hard filtering, we identified 84 reported or novel nonsynonymous variants, 22 of which have been previously associated with disease. Using computational prediction methods, 20 of the remaining 62 variants were predicted to be dele- terious. Consistent with published data, nearly one half of these 42 variants (19; 45%) were found in genes implicated in the pathogenesis of aHUS. Several genes in the coagulation pathway were also identified as important in the pathogenesis of aHUS.
    [Show full text]
  • A MASP-1 Által Indukált Proinflammatorikus Válasz, És Ezen Belül Az Adhéziós Tulajdonságok Vizsgálata Endotélsejtekben
    A MASP-1 által indukált proinflammatorikus válasz, és ezen belül az adhéziós tulajdonságok vizsgálata endotélsejtekben Doktori értekezés Schwaner Endre Semmelweis Egyetem Elméleti és Transzlációs Orvostudományok Doktori Iskola Témavezető: Dr. Cervenak László, Ph.D., tudományos főmunkatárs Hivatalos bírálók: Dr. Jeney Viktória, Ph.D., tudományos főmunkatárs Dr. Káldi Krisztina, Ph.D., egyetemi docens Szigorlati bizottság elnöke: Dr. Kellermayer Miklós, az MTA doktora, egyetemi tanár Szigorlati bizottság tagjai: Dr. Uzonyi Barbara, Ph.D., tudományos munkatárs Dr. Láng Orsolya, Ph.D., egyetemi docens Budapest 2019 TARTALOMJEGYZÉK 1. RÖVIDÍTÉSEK JEGYZÉKE ....................................................................................... 5 2. BEVEZETÉS ................................................................................................................ 8 2.1. A KOMPLEMENTRENDSZER ........................................................................... 9 2.1.1. A lektin út és a MBL-asszociált szerint proteázok ........................................ 11 2.2. A GYULLADÁS FOLYAMATA ....................................................................... 14 2.3. AZ ENDOTÉLSEJTEK ....................................................................................... 17 2.3.1. Az endotélsejtek funkciói .............................................................................. 18 2.3.1.1. Szelektív barrier képzés .......................................................................... 19 2.3.1.2. A vaszkuláris tónus szabályozása
    [Show full text]
  • Hypoxia Restrains the Expression of Complement Component 9 in Tumor
    Li et al. Cell Death Discovery (2018) 4:63 DOI 10.1038/s41420-018-0064-3 Cell Death Discovery ARTICLE Open Access Hypoxia restrains the expression of complement component 9 in tumor- associated macrophages promoting non- smallcelllungcancerprogression Lei Li1, Hong Yang1,2,3, Yan Li1, Xiao-Dong Li1,3, Ting-Ting Zeng1,Su-XiaLin4,Ying-HuiZhu1 and Xin-Yuan Guan 1,5 Abstract The tumor microenvironment, including stroma cells, signaling molecules, and the extracellular matrix, critically regulates the growth and survival of cancer cells. Dissecting the active molecules in tumor microenvironment may uncover the key factors that can impact cancer progression. Human NSCLC tumor tissue-conditioned medium (TCM) and adjacent nontumor tissue-conditioned medium (NCM) were used to treat two NSCLC cells LSC1 and LAC1, respectively. Cell growth and foci formation assays were applied to assess the effects of TCM and NCM on cancer cells. The active factors were identified by protein mass spectrometry. Cell growth and foci formation assays showed that 8 of 26 NCM and none of TCM could effectively lead to tumor cell lysis, which was known as tumoricidal activity. And then protein mass spectrometry analysis and functional verifications confirmed that complement component 9 (C9) played a crucial role in the complement-dependent cytotoxicity (CDC)-mediated tumoricidal activity in vitro. Furthermore, immunofluorescent staining revealed that C9 specifically expressed in most alveolar macrophages (AMs) 1234567890():,; 1234567890():,; 1234567890():,; 1234567890():,; in adjacent lung tissues and a small fraction of tumor-associated macrophages (TAMs) in NSCLC tissues. Most importantly, the percentage of C9-positive cells in AMs or TAMs was responsible for the tumoricidal activity of NCM and TCM.
    [Show full text]
  • The Complement System and Cardiovascular Disease
    The complement system and cardiovascular disease Citation for published version (APA): Hertle, E. (2016). The complement system and cardiovascular disease: the CODAM study. https://doi.org/10.26481/dis.20160401eh Document status and date: Published: 01/01/2016 DOI: 10.26481/dis.20160401eh Document Version: Publisher's PDF, also known as Version of record Please check the document version of this publication: • A submitted manuscript is the version of the article upon submission and before peer-review. There can be important differences between the submitted version and the official published version of record. People interested in the research are advised to contact the author for the final version of the publication, or visit the DOI to the publisher's website. • The final author version and the galley proof are versions of the publication after peer review. • The final published version features the final layout of the paper including the volume, issue and page numbers. Link to publication General rights Copyright and moral rights for the publications made accessible in the public portal are retained by the authors and/or other copyright owners and it is a condition of accessing publications that users recognise and abide by the legal requirements associated with these rights. • Users may download and print one copy of any publication from the public portal for the purpose of private study or research. • You may not further distribute the material or use it for any profit-making activity or commercial gain • You may freely distribute the URL identifying the publication in the public portal. If the publication is distributed under the terms of Article 25fa of the Dutch Copyright Act, indicated by the “Taverne” license above, please follow below link for the End User Agreement: www.umlib.nl/taverne-license Take down policy If you believe that this document breaches copyright please contact us at: [email protected] providing details and we will investigate your claim.
    [Show full text]
  • Derivation of Ligands for the Complement C3a Receptor from the C-Terminus of C5a
    This is a repository copy of Derivation of ligands for the complement C3a receptor from the C-terminus of C5a. White Rose Research Online URL for this paper: http://eprints.whiterose.ac.uk/99926/ Version: Submitted Version Article: Halai, R., Bellows-Peterson, M.L., Branchett, W. et al. (8 more authors) (2014) Derivation of ligands for the complement C3a receptor from the C-terminus of C5a. European Journal of Pharmacology, 745. pp. 176-181. ISSN 0014-2999 https://doi.org/10.1016/j.ejphar.2014.10.041 Reuse This article is distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs (CC BY-NC-ND) licence. This licence only allows you to download this work and share it with others as long as you credit the authors, but you can’t change the article in any way or use it commercially. More information and the full terms of the licence here: https://creativecommons.org/licenses/ Takedown If you consider content in White Rose Research Online to be in breach of UK law, please notify us by emailing [email protected] including the URL of the record and the reason for the withdrawal request. [email protected] https://eprints.whiterose.ac.uk/ Derivation of ligands for the complement C3a receptor from the C- terminus of C5a Reena Halaia,*, Meghan L Bellows-Petersonb,*, Will Branchettc, James Smadbeckb, Chris A Kieslichb, Daniel E Crokera, Matthew A Coopera, Dimitrios Morikisd, Trent M Woodruffe, Christodoulos A Floudasb,#, Peter N Monkc,# *equal contributing authors #equal corresponding authors ([email protected]; tel.
    [Show full text]
  • Functions of the Complement Components C3 and C5 During Sepsis
    The FASEB Journal • Research Communication Functions of the complement components C3 and C5 during sepsis Michael A. Flierl,*,1 Daniel Rittirsch,*,1 Brian A. Nadeau,* Danielle E. Day,* Firas S. Zetoune,* J. Vidya Sarma,* Markus S. Huber-Lang,† and Peter A. Ward*,2 *Department of Pathology, University of Michigan Medical School, Ann Arbor, Michigan, USA; and †Department of Trauma-, Hand- and Reconstructive Surgery, University of Ulm Medical School, Ulm, Germany ABSTRACT Activation of the complement system is a mia (2, 3). Thus, some clinicians preferably refer to this key event in the pathogenesis of sepsis. Nevertheless, complex of symptoms as “sepsis syndrome.” It is of the exact mechanisms remain inadequately understood. concern that doctors have seen a rapid increase in In the current study, we examined the role of comple- hospitalization and mortality rates for severe sepsis in ment C3 and C5 in sepsis in wild-type and C3- or the United States between 1993 and 2003 while mortal- C5-deficient mice induced by cecal ligation and punc- ity rates only slightly decreased (4). During this 11-year ؊/؊ ture. When compared to wild-type mice, C5 showed period, the hospitalization rate has almost doubled and ؊/؊ identical survival, and C3 presented significantly is considerably higher than it has been previously reduced survival. Interestingly, this was associated with predicted, making septicemia now the 10th leading significant decreases in plasma levels of proinflamma- .(؊/؊ cause of death in the United States. (5 tory mediators. Moreover, although septic C3 ani- Encroachment of pathogens prompts the comple- mals displayed a 10-fold increase of blood-borne bac- ؊/؊ ment cascade, which plays a decisive role in the host’s teria, C5 animals exhibited a 400-fold increase in immune response (1, 6).
    [Show full text]
  • Identification of a Novel Mutation in the C6 Gene of a Han Chinese C6SD Child with Meningococcal Disease
    EXPERIMENTAL AND THERAPEUTIC MEDICINE 21: 510, 2021 Identification of a novel mutation in the C6 gene of a Han Chinese C6SD child with meningococcal disease AI‑QIAN ZHANG1*, YU‑XING LIU2*, JIE‑YUAN JIN2, CHEN‑YU WANG2, LIANG‑LIANG FAN2,3 and DA‑BAO XU1 1Department of Obstetrics and Gynecology, The Third Xiangya Hospital of Central South University, Changsha, Hunan 410011; 2Department of Cell Biology; 3Hunan Key Laboratory of Animals for Human Disease, School of Life Sciences, Central South University, Changsha, Hunan 410013, P.R. China Received July 18, 2020; Accepted February 5, 2021 DOI: 10.3892/etm.2021.9941 Abstract. Deficiency of the sixth complement component against invading pathogens (2). Genetic deficiencies of any of (C6D) is a genetic disease associated with increased suscep‑ the terminal complement components lead to failure to form tibility to Neisseria meningitides infection. Individuals with the MAC and susceptibility to Neisseria meningitides (Nm) C6D usually present with recurrent meningococcal disease infections, the so‑called terminal complement component (MD). According to the patients' C6 levels, C6D is divided deficiencies (TCCD) (3). into complete genetic deficiency of C6 and subtotal deficiency As one of five terminal complement components, the sixth of C6 (C6SD). The present study reported on a Han Chinese complement component (C6) is a constituent of the MAC. pediatric patient with MD, in whom further investigation Deficiency of C6 (C6D; Online Mendelian Inheritance in Man revealed a C6SD genetic lesion. A heterozygote nonsense #612446) is associated with increased susceptibility to Nm mutation (c.1062C>G/p.Y354*) in the C6 gene was identified infections and patients with C6D usually present with recurrent by Sanger sequencing.
    [Show full text]